AIM: This work aimed to determine if the treatment outcomes of bladder cancer could be improved by targeting micelles that are decorated with bladder cancer-specific ligands on the surface and loaded with the chemotherapeutic drug paclitaxel. MATERIALS & METHODS: Targeting efficacy and specificity was determined with cell lines. An in vivo targeting and anti-tumor efficacy study was conducted in mice carrying patient-derived xenografts. RESULTS & DISCUSSION: Targeting micelles were more efficient than nontargeting micelles in delivering the drug load into bladder cancer cells both in vitro and in vivo (p < 0.05). The micelle formulation of paclitaxel was less toxic than free paclitaxel in Cremophor(®) (Sigma, MO, USA) and allowed administration of three-times the maximum tolerated dose without increasing the toxicity. Targeting micelles were more effective than the nontargeting micelles in controlling cancer growth (p = 0.0002) and prolonging overall survival (p = 0.002). CONCLUSION: Targeting micelles loaded with paclitaxel offer strong potential for clinical applications in treating bladder cancer.
AIM: This work aimed to determine if the treatment outcomes of bladder cancer could be improved by targeting micelles that are decorated with bladder cancer-specific ligands on the surface and loaded with the chemotherapeutic drug paclitaxel. MATERIALS & METHODS: Targeting efficacy and specificity was determined with cell lines. An in vivo targeting and anti-tumor efficacy study was conducted in mice carrying patient-derived xenografts. RESULTS & DISCUSSION: Targeting micelles were more efficient than nontargeting micelles in delivering the drug load into bladder cancer cells both in vitro and in vivo (p < 0.05). The micelle formulation of paclitaxel was less toxic than free paclitaxel in Cremophor(®) (Sigma, MO, USA) and allowed administration of three-times the maximum tolerated dose without increasing the toxicity. Targeting micelles were more effective than the nontargeting micelles in controlling cancer growth (p = 0.0002) and prolonging overall survival (p = 0.002). CONCLUSION: Targeting micelles loaded with paclitaxel offer strong potential for clinical applications in treating bladder cancer.
Authors: Kai Xiao; Juntao Luo; Wiley L Fowler; Yuanpei Li; Joyce S Lee; Li Xing; R Holland Cheng; Li Wang; Kit S Lam Journal: Biomaterials Date: 2009-08-05 Impact factor: 12.479
Authors: Shaguna Seth; Yoshiyuki Matsui; Kathy Fosnaugh; Yan Liu; Narendra Vaish; Roger Adami; Pierrot Harvie; Rachel Johns; Gregory Severson; Tod Brown; Akihide Takagi; Susan Bell; Yan Chen; Feng Chen; Tianying Zhu; Renata Fam; Iwona Maciagiewicz; Erin Kwang; Michael McCutcheon; Ken Farber; Patrick Charmley; Michael E Houston; Alan So; Michael V Templin; Barry Polisky Journal: Mol Ther Date: 2011-03-01 Impact factor: 11.454
Authors: Yuanpei Li; Wenwu Xiao; Kai Xiao; Lorenzo Berti; Juntao Luo; Harry P Tseng; Gabriel Fung; Kit S Lam Journal: Angew Chem Int Ed Engl Date: 2012-01-17 Impact factor: 15.336
Authors: Suzie H Pun; Frederik Tack; Nathalie C Bellocq; Jianjun Cheng; Brendan H Grubbs; Gregory S Jensen; Mark E Davis; Marcus Brewster; Michel Janicot; Boudewijn Janssens; Wim Floren; Annette Bakker Journal: Cancer Biol Ther Date: 2004-07-09 Impact factor: 4.742
Authors: Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner Journal: Cold Spring Harb Protoc Date: 2014-07-01
Authors: Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner Journal: Cold Spring Harb Protoc Date: 2014-07-01
Authors: Hongyong Zhang; Yuanpei Li; Tzu-Yin Lin; Kai Xiao; Ashraf S Haddad; Paul T Henderson; Brian A Jonas; Mingyi Chen; Wenwu Xiao; Ruiwu Liu; Kit S Lam; Chong-xian Pan Journal: Nanomedicine (Lond) Date: 2014-03-17 Impact factor: 5.307